Seattle, WA (PRWEB) April 16, 2012
Cami Gearhart and Linda Coleman, Quorum Review IRB’s CEO and Director of Regulatory Affairs & General Counsel respectively, will present at this year’s AAHRPP Conference, “Quality Human Research Protection Programs: Protecting Vulnerable Populations.”
Ms. Gearhart will be a co-presenter on the topic of “Metrics and Monitoring” during the Thursday, April 19 session. Ms. Coleman’s presentation, “Reviewing Protocols: Establishing and Using Tissue Banks and Data Registries,” occurs on April 20th. Quorum Review will also host Booth #7 on the exhibitor floor, where conference attendees can discuss the latest in central IRB services with their Quorum Review colleagues in person.
Held in Denver, CO, from April 18-20th, the AAHRPP conference offers programs that support AAHRPP’s mission of promoting high-quality research through an accreditation process that helps organizations worldwide strengthen their human research protection programs. Additionally, attendees will benefit from the opportunity to collaborate with leading experts in the clinical trial industry as well as improving knowledge regarding organizational requirements for AAHRPP accreditation. More information about the 2012 conference is available on the AAHRPP website.
About Quorum Review
Quorum Review is an independent ethics review board fully accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP), and has been providing ethics review of drug and device trials since 1992. Quorum oversees research in accordance with U.S. and Canadian human research subject protection regulations and guidelines set forth by the International Committee on Harmonisation (ICH), and principles of the Belmont Report.
Quorum’s best-in-class service and support includes 13 Board meetings each week plus expedited review, 24 hour site review turnaround, 36 hour amendment review turnaround, a secure web portal, and Smart Forms for online submissions. Quorum’s full service offerings include full study review in the US and Canada, a specialized Phase I team, and unique processes for post-approval and registry studies.